Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Human Polyclonal SMARCA4 Primary Antibody für ChIP, ICC - ABIN4285245
Miyamoto, Pasque, Jullien, Gurdon: Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes. in Genes & development 2011
Show all 4 Pubmed References
Human Polyclonal SMARCA4 Primary Antibody für WB - ABIN686122
Chen, Han, Wei, Zhang, Shi, Duan, Li, Zhou, Pu, Zhang, Kang: SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. in Scientific reports 2015
Human Monoclonal SMARCA4 Primary Antibody für ICC, IF - ABIN2668499
Ohkawa, Harada, Nakamura, Yoshimura, Tachibana: Production of a rat monoclonal antibody against Brg1. in Hybridoma (2005) 2009
Human Monoclonal SMARCA4 Primary Antibody für ICC, IF - ABIN2668498
de la Serna, Ohkawa, Higashi, Dutta, Osias, Kommajosyula, Tachibana, Imbalzano: The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes. in The Journal of biological chemistry 2006
Depletion of Brg1 improves the integrity of airway epithelium in asthma by regulating E-cadherin (zeige CDH1 Antikörper) expression in lung epithelial cells. Knockdown of Brg1 increased the cell proliferation and migration by human bronchial epithelial 16HBE cells.
High BRG1 expression is associated with leukemia and lymphoma.
HDAC9, in cooperation with BRG1 and MALAT1, mediates a critical epigenetic pathway responsible for vascular smooth muscle cells dysfunction.
SMARCA4-deficient thoracic sarcomas constitute a unique, highly lethal entity that requires full recognition and differentiation from other epithelioid malignancies involving the thoracic region.
The outcome following a diagnosis of any of these tumors is often poor, and the value of surveillance is unknown. International efforts to determine surveillance protocols are underway, and preliminary recommendations are made for carriers of SMARCB1 (zeige SMARCB1 Antikörper) and SMARCA4 mutations.
Study identified DNA methylation (zeige HELLS Antikörper) (DNAm) site, cg07786668 in ZFHX3 (zeige ZFHX3 Antikörper) that is independently and significantly associated with myocardial infarction (MI) along with cg17218495 in SMARCA4. These results suggest that the development of MI might be influenced by changes in DNAm at these sites via a pathway that differs from that affected by cardiovascular disease-associated SNPs in these genes.
Authors demonstrate that BRG1 upregulates de novo lipogenesis and that this is crucial for cancer cell proliferation. Knockdown of BRG1 attenuates lipid synthesis by impairing the transcription of enzymes catalyzing fatty acid and lipid synthesis.
SMARCA4 SNPs are associated with coronary heart disease development in Chinese Han population.
BRG1 may contribute to colon cancer progression through upregulating WNT3A (zeige WNT3A Antikörper) expression.
We also demonstrate that tazemetostat, a potent and selective EZH2 (zeige EZH2 Antikörper) inhibitor currently in phase II clinical trials, induces potent antiproliferative and antitumor effects in SCCOHT cell lines and xenografts deficient in both SMARCA2 (zeige SMARCA2 Antikörper) and SMARCA4. These results exemplify an additional class of rhabdoid-like tumors that are dependent on EZH2 (zeige EZH2 Antikörper) activity for survival.
Data found that Brg1 played important roles in hair cells (HCs (zeige HLCS Antikörper)) intrinsic polarity maintenance, anchoring outer hair cells base to the Deiter's cells and scar formation of the auditory epithelium. These results demonstrated a requirement for Brg1 activity in development and suggested a role for Brg1 in the proper cellular structure formation of HCs (zeige HLCS Antikörper).
The results demonstrated that restoration of Brg1 during reperfusion could enhance Nrf2 (zeige NFE2L2 Antikörper)-mediated inducible expression of HO-1 (zeige HMOX1 Antikörper) during hepatic ischemia-reperfusion injury to effectively increase antioxidant ability to combat against hepatocytes damage.
BAF (zeige BANF1 Antikörper) (BRG1/BRM (zeige SMARCA2 Antikörper)-Associated Factor) chromatin-remodeling complex may adaptively respond to ethanol exposure to protect against a complete loss of miR (zeige MLXIP Antikörper)-9-2 in fetal neural stem cells.
Chromatin accessibility at OCT4 (zeige POU5F1 Antikörper)-bound sites requires the chromatin remodeller BRG1, which is recruited to these sites by OCT4 (zeige POU5F1 Antikörper) to support additional transcription factor binding and expression of the pluripotency-associated transcriptome.
Data (including data from studies using knockout mice) suggest that Brg1 is phosphorylated by casein kinase 2 (Ck2 (zeige CSNK2A1 Antikörper); Ck2alpha1 and Ck2alpha-prime are catalytic subunits) in proliferating skeletal myoblasts; Brg1 is catalytic subunit of SWI (zeige SMARCA1 Antikörper)/SNF (zeige SNRPA Antikörper) chromatin-remodeling enzymes; Ck2 (zeige CSNK2A1 Antikörper)-mediated phosphorylation of Brg1 appears to regulate myoblast proliferation. (Brg1 = Brahma (zeige SMARCA2 Antikörper)-related gene 1 protein)
BRG1 is a SOX10 (zeige SOX10 Antikörper) co-activator, required to establish the melanocyte lineage and promote expression of genes important for melanocyte function.
n keratinocytes, the promoter-enhancer anchoring regions in the gene-rich transcriptionally active TADs are enriched for the binding of chromatin architectural proteins CTCF (zeige CTCF Antikörper), Rad21 (zeige RAD21 Antikörper) and chromatin remodeler Brg1. In contrast to gene-rich TADs, gene-poor TADs show preferential spatial contacts with each other, do not contain active enhancers and show decreased binding of CTCF (zeige CTCF Antikörper), Rad21 (zeige RAD21 Antikörper) and Brg1 in keratinocytes
Data demonstrate that Brg1 plays an essential role in development and homeostasis, including morphogenesis, stem cell differentiation and cell survival in the duodenum.
Point mutations in SMARCA4 (also known as BRG1) mapping to the ATPase (zeige DNAH8 Antikörper) domain cause loss of direct binding between BAF (zeige BANF1 Antikörper) and PRC1 (zeige PRC1 Antikörper).
The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene.
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4
, transcription activator BRG1-like
, ATP-dependent helicase SMARCA4
, BRG1-associated factor 190A
, BRM/SWI2-related gene 1
, SNF2-like 4
, brahma protein-like 1
, global transcription activator homologous sequence
, homeotic gene regulator
, mitotic growth and transcription activator
, nuclear protein GRB1
, protein BRG-1
, protein brahma homolog 1
, sucrose nonfermenting-like 4
, transcription activator BRG1
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
, SWI/SNF related transcriptional activator
, WI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4